A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia - No Study Results Posted - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

This study has been completed.

Study NCT00398710 Information provided by Keryx / AOI Pharmaceuticals, Inc.

First Received: November 9, 2006 Last Updated: November 10, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	October 2011
Primary Completion Date:	August 2011 (Final data collection date for primary outcome measure)

Publications:

Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res. 2010 Feb 1;16(3):1033-41. Epub 2010 Jan 26.

Back to top of Main Content